Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)

NCT02546284 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myelomonocytic Leukemia (CMML)

Interventions

DRUG: lenzilumab

Sponsor

Humanigen, Inc.